WebApr 11, 2024 · On average, analysts predict that Dyne Therapeutics will post -3.23 EPS for the current year. Insider Activity at Dyne Therapeutics. In related news, insider Jonathan Mcneill sold 10,000 shares of the company's stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of … WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving …
Press Releases Dyne Therapeutics
WebView the latest Dyne Therapeutics Inc. (DYN) stock price, news, historical charts, analyst ratings and financial information from WSJ. WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1). binding of isaac cricket\u0027s head
Dyne Therapeutics launches with $50 million for oligonucleotide …
WebMar 23, 2024 · Dyne Therapeutics, Inc. announced that DYNE-251, an investigational therapeutic for Duchenne muscular dystrophy mutations amenable to exon 51 skipping, was granted FDA orphan drug and rare pediatric disease designations.DYNE-251 is being evaluated in the Phase 1/2 DELIVER clinical trial. Under the FDA's rare pediatric disease … WebOct 31, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … WebGet the latest Dyne Therapeutics Inc (DYN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment … binding of isaac crossplay